The Cure for Alexion
Alexion Pharmaceuticals (ALXN) is niche player in the biotech space, focusing on severe ultra-rare diseases that affect, at most, one out of every 50,000 people.
The Connecticut-based company's emerging business model is to develop drugs for diseases where there is essentially no competition. Soliris, Alexion's only drug on the market to date, is the only drug approved to treat a rare life-threatening blood disorder called paroxysmal nocturnal hemoglobinuria, or PNH, that attacks red blood cells. The monopoly gives Alexion remarkable high pricing power; a year's course of Soliris costs around $400,000....457 more words left in this article. To read them, just click below and try Real Money FREE for 14 days.
There’s no substitute for a trading floor to get great ideas, so Jim Cramer created a better one at Real Money and blogs there exclusively. We then added legendary hedge fund manager, Doug Kass, with his exclusive Daily Diary and best investing ideas. Staffed with more than 4 dozen investing pros, money managers, journalists and analysts, Real Money Pro gives you a flood of opinions, analysis and actionable trading advice found nowhere else, and allows you to interact directly with each expert.
Already a Subscriber? Please login.